Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single dose of tocilizumab clear the way for a second kidney transplant?

NCT ID NCT04779957

Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 pilot study tested whether a single dose of tocilizumab, given before or after removing a failed kidney transplant, is safe and can reduce harmful antibodies that make a second transplant difficult. The study involved 18 adults who needed their kidney graft removed and hoped for another transplant. The main focus was on serious infections, but researchers also looked at overall complications and antibody levels one year later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tocilizumab
What this could lead to
If it works, this could help people who lose a kidney transplant have a better chance of getting a second one by reducing immune system barriers.
What could go wrong
This is a small, early-phase pilot study with only 18 participants, so results may not apply to everyone. The drug may also increase the risk of serious infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

18 people

The number who actually took part.

Started

Oct 2021

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult recipients, * affiliated to the social security * requiring a graft nephrectomy, with a project to retransplantation Exclusion Criteria: * combined transplantations, PRA \>20%. * Patient under protective measures, * Rituximab used for immunosuppression induction * Previous transplants not removed, * Active infectious complications at graft nephrectomy, need for immunosuppressive treatments after graft nephrectomy, * Participation to another interventional studies using Rituximab, polyclonal antibodies, Eculizumab, or Tocilizumab. * adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision, * pregnancy or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graft failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graft failure Kidney transplantation

Contacts and locations

Locations

  • CHU Toulouse

    Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.